Literature DB >> 16629648

Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study.

Revital Kariv1, Moshe Leshno, Anat Beth-Or, Hana Strul, Laurie Blendis, Ehud Kokia, Dina Noff, Shira Zelber-Sagie, Bracha Sheinberg, Ran Oren, Zamir Halpern.   

Abstract

BACKGROUND: The upper normal limit (ULN) of serum alanine-aminotrasferase (ALT) normal range was recently challenged, because patients diagnosed with liver diseases may have 'normal' or near-'normal' ALT levels, and because possible modulators are often ignored in determining normal range. AIM: To estimate the ULN for serum ALT and to identify factors modulating it. SUBJECTS AND METHODS: We reviewed medical records of subjects aged 15-90, who underwent standard panels of laboratory tests, including serum ALT, over 6 months at a central laboratory. Three groups were defined: Group 1, comprised total study population (N=272 273). Group 2 (N=87 020) comprised total study population, excluding those receiving potentially hepatotoxic drugs, or diagnosed with liver disease, or had any abnormal laboratory test results other than for triglycerides, cholesterol, glucose, or HbA1c. Group 3 (N=17 496) the 'healthy' population, from whose ALT values we established the new ULN, comprised Group 2 subjects with normal triglycerides, cholesterol, glucose, and HbA1c levels.
RESULTS: The 95th percentile ALT values, corresponding to the ULN, in groups 1, 2, and 3 were 50.1, 40, and 37.5 U/l, respectively. 6.2% (16 943/273 273) of subjects whose ALT was below ULN listed by the test manufacturer (52 U/l), had ALT level above our new ULN. Linear and logistic-regression analyses showed that ALT levels were significantly modified by gender, age, glucose, cholesterol, triglycerides, and overweight/obesity diagnosis. Significant interaction was found between gender, glucose and cholesterol levels.
CONCLUSIONS: In this first large-scale study of 'healthy' population, serum ALT ULN was far lower than currently accepted value. Age and gender may be considered when determining the ULN for ALT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629648     DOI: 10.1111/j.1478-3231.2006.01197.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  38 in total

1.  Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival.

Authors:  Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi; Antonio Picardi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-06-14       Impact factor: 6.053

Review 2.  From bed to bench: which attitude towards the laboratory liver tests should health care practitioners strike?

Authors:  Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

3.  Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline.

Authors:  Zhaohui Cai; Anastasia M Christianson; Lars Ståhle; Marianne Keisu
Journal:  Eur J Clin Pharmacol       Date:  2009-06-25       Impact factor: 2.953

Review 4.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

5.  Upper limits of normal for alanine aminotransferase activity in the United States population.

Authors:  Constance E Ruhl; James E Everhart
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

6.  Management of hepatitis B in developing countries.

Authors:  Zaigham Abbas; Adeel R Siddiqui
Journal:  World J Hepatol       Date:  2011-12-27

Review 7.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

8.  Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Geraldine J Ooi; Paul R Burton; Lisa Doyle; John M Wentworth; Prithi S Bhathal; Ken Sikaris; Michael A Cowley; Stuart K Roberts; William Kemp; Arul Earnest; Paul E O'Brien; Wendy A Brown
Journal:  Obes Surg       Date:  2017-06       Impact factor: 4.129

9.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

10.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.